Transaction Summary:
On October 30, 2007, Clorox Co. ("Clorox") announced the acquisition of Burt's Bees
("Burt's" or the "Company") for $925 million in cash, net of an additional $25 million
payment for anticipated tax benefits. Burt's represents a new strategic direction
for Clorox and its first entry into the personal care category. The offer represents a
multiple of Burt’s estimated calendar 2007 net sales of 5.4X, and a multiple of Burt's
estimated 2007 EBITDA of approximately 18.1X. Clorox did not quantify anticipated
synergies. In fact, Clorox management emphasized that the valuation was based, instead,
on Burt's inherent historical growth rate, the near-term opportunities to expand US
distribution in food, drug and mass ("FDM") channels, and the potential to expand the brand into natural
adjacencies. Clorox expects to finance the transaction with cash and short term borrowings.
At closing, expected at the end of December 2007, Clorox anticipates that its debt to
EBITDA ratio will be 3.5X (up from 2.6X prior to the deal). Clorox plans to return to
its target debt to EBITDA ratio of 3.0X by the end of calendar 2009. Excluding
purchase-accounting adjustments, one time-transaction costs and integration costs
(not quantified), Clorox announced that the transaction is anticipated to be earnings neutral in
its Fiscal 2008 (ending June 30th, 2008) and "solidly" accretive thereafter.
Business Overview:
Burt's is one of the leading brands in the growing $6.4 billion natural personal care
("NPC") segment. The company was co-founded in 1989 by Roxanne Quimby and is headquartered
in Durham, North Carolina. With expected calendar 2007 net sales of approximately $170 million,
the Company is best known for its Lip Care product line, which makes up 40% of the total and
is growing at a double digit rate. Burt's also commands a #1 or #2 position (within the natural
food channels) in four other categories: Foot Care, Kits and Gifts, Baby Care, and Other
Skin Care. Facial and Body Care represent approximately 30% of sales and Infant Care, Kits and
Gifts, Outdoor/Natural Remedies and Other make up the balance, approximately 30% of sales.
The Company’s products are positioned as simple, trusted and effective alternatives to
synthetic, mainstream products, and are made with natural ingredients. Burt's formulations
use fruits, vegetables, natural preservatives and botanical oils and are packaged in recycled
and recyclable materials. The elements of the brand’s distinctive positioning have made Burt's one of the few natural personal care brands that appeal to a broad range of consumers
beyond those in the natural products segment. These include: Burt's unconventional personality,
innovative and efficacious products, diversified product line, strong sense of values, and
highly-recognizable, bold, simple and eye-catching graphics and packaging. Burt's strong brand
equity is also reflected in consumers' superior rating of the brand versus its competitors
across all important criteria such as efficacy, quality, safety, and composition. Over the years,
Burt's brand aided awareness has grown to competitive levels while well ahead of other natural players.
Over the past four years, Burt's has grown at a compound annual rate of over 30% and has expanded well
beyond its original roots in health food and other natural products channels, reaching an all commodity
value ("ACV") of 54% in food, drug and mass ("FDM") channels in the most recent twelve-month period (compared with 4% in 2002).
See below for Burt’s expanding in-store presence in the traditional channels over the last three years.
Strategic Rationale:
On the investor conference call Clorox management made it very clear that their overriding strategic objective was to
accelerate top line growth. Clorox recognizes that the convergence of consumer mega-trends toward sustainability
and health and wellness will provide a favorable growth "tail wind". In addition, natural personal care
represents an economically attractive category in light of its scale ($6.4 billion), expected growth rate (7.7% projected annual growth),
low household penetration (12%) and high fragmentation (top five players represent less than 20% of the total market). Thus,
the acquisition provides the opportunity to acquire a "scale" brand, with leading market positions, in a category not dominated by other
large consumer package goods companies. Furthermore, Clorox plans to use Burt’s as a platform for expansion into other personal care and health and wellness segments.
For Clorox, the acquisition also represents a move toward higher margin and higher growth consumer categories.
Burt’s EBITDA margin is estimated to be greater than 30%, compared with Clorox’s 22% EBITDA margin.
While Burt’s $170 million in sales will only represent 3.4% of Clorox’s nearly $5 billion in 2007 sales, Clorox
management has indicated that it expects the acquisition will drive an additional 2 percentage points of growth
on top of Clorox's organic growth rate of 4-5%.
Clorox envisions multiple pathways to sustain long-term growth through US
distribution upside, international expansion, and extending the brand into new categories.
Significant distribution upside exists in FDM channels, where Clorox’s 100% ACV compares
to Burt’s 60% ACV. Clorox expects to be able to leverage its deep distribution relationships with FDM channels to increase Burt’s shelf
presence and continue to drive growth. In addition, the Burt’s Bees brand is eminently extendable into other categories, as consumers
view it to be the "most natural" personal care brand (according to a Clorox-commissioned survey). Overall, the transaction allows Clorox
to acquire an authentic and competitively advantaged brand with unique formulation and manufacturing capabilities, a strong consumer
franchise, top-tier profitability, and an experienced and credible management team.
M&A Considerations:
Burt’s was acquired by AEA Investors ("AEA") in November 2003 for an estimated $175 million. At the time, Burt’s had sales of
approximately $55 million and a reported EBITDA of approximately $20 million. As such, the transaction multiples paid by AEA were
3.2x net sales and almost 9x EBITDA. These were perceived as high at the time.
Clorox acquired Burt’s Bees in a competitive process. Our intelligence indicates that about 10 strategic entities were approached about the opportunity.
A number of leading personal care and cosmetics players did not pursue the transaction. In addition to Clorox, we believe that SC Johnson,
Colgate and Unilever participated in the process. Industry sources indicate that SC Johnson was Clorox's key competitor in the final stages
with a final offer that was meaningfully lower than the price paid by Clorox.
The transaction multiples paid by Clorox are at the very high end of comparable multiples paid in similar leading branded personal care transactions
as shown in the chart below.
Analysts’ Reaction:
While we can appreciate that there is a scarcity of attractive acquisitions available in the HPC universe, we are surprised that
CLX agreed to pay such a high price, particularly as we expect that any expanded distribution for Burt’s products will most likely
come at a cost to those very strong 30% EBITDA margins.
Citigroup – October 31, 2007
Burt's is a great brand, we strongly agree with Clorox on the mega-trend and believe the acquisition has the potential to significantly
speed up growth, but the beauty business moves much faster than Clorox's core categories so it seems like a stretch from an execution
standpoint and will need to be proven out over time.
Bank of America – November 1, 2007
Despite an overwhelmingly poor history of deals in the HPC universe, we would expect the CLX shares to outperform anyway,
and would point out the relatively modest size of the Burt’s deal (~3.5% of CLX sales). Our discounted cash flow analysis (see below) shows that the $925 million purchase price can be justified with quite realistic growth and margin projections.
Merrill Lynch – November 1, 2007
We have to say that we find the acquisition a little puzzling. The company does not have a personal care business that they can leverage for the new brands. While there may be some strategic benefits as they try to move their portfolio towards more organic/natural products, we’re not sure we really understand the rationale. Especially since the deal will not drive economic profit for more than 5 years.
JP Morgan – November 1, 2007
The Burt’s acquisition is not an obvious fit for Clorox and we believe it represents a new challenge for management given the entre into a new and unrelated category. Valuation is high relative to past HPC deal's at 5.4X sales.
Goldman Sachs – October 31, 2007
Sources:
Company filings, equity research, Company press releases, Company investor presentations, CapitalIQ, Euromonitor, Datamonitor, Nutrition Business Journal, The Deal, IRI Food, Drug and Mass ("FDM")x 52-weeks ending October 7, 2007